title: Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection.
abstract: The aim of this work was to confirm our preliminary clinical and immunological evaluation of the protective effects of a herpes simplex virus (HSV) vaccine derived from killed virus in the treatment of relapsing facial or genital herpes simplex infection. A total of 142 patients were treated with the HSV vaccine and a control group of 50 were treated with intermittent oral acyclovir (ACV). The vaccine reduced annual active disease days in vaccinees to 11.59 (+/- 15.3) after treatment (65.11 +/- 31.64 before treatment) compared to 30.4 +/- 17.49 days after treatment of the control group patients (71.86 +/- 32.5 before treatment).
authors.affiliation: Department of Dermatology, STD & AIDS Center, University of Florence, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Mastrolorenzo
authors.forename: L
authors.initials: L
authors.lastname: Tiradritti
authors.forename: L
authors.initials: L
authors.lastname: Salimbeni
authors.forename: G
authors.initials: G
authors.lastname: Zuccati
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control; D006561:Herpes Simplex / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D018259:Herpesvirus 1, Human / Q000276:immunology*; D018258:Herpesvirus 2, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D017778:Vaccines, Combined / Q000276:immunology* / Q000494:pharmacology; D015164:Vaccines, Inactivated / Q000276:immunology / Q000627:therapeutic use*; D017735:Virus Latency
chemical_list: D000998:Antiviral Agents; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated; D000212:Acyclovir